Accessibility Menu
Cardiol Therapeutics logo

Cardiol Therapeutics(NASDAQ) CRDL

Market Cap$151.01MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)-66%
5 Year-39%
1 Year-5%
1 Month+25%
$1.32
+3.54%
+0.04Today
After hours$1.31-$0.00 (-0.38%)
Cardiol Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 1.312026-08-03
Cardiol Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+13.42%USD 1.162026-07-27
1 month+24.76%USD 1.052026-07-02
3 month+0%USD 1.312026-05-05
Year to date+37.35%USD 0.952025-12-31
1 year-5.07%USD 1.382025-08-01
3 year+11.97%USD 1.172023-08-04
5 year-39.07%USD 2.152021-08-04
Since inception-66.06%USD 3.742019-01-15

Cardiol Therapeutics Financials at a Glance

Market Cap

$151.01MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CA$0.00

Net Income (TTM)

-CA$36.38M

EPS (TTM)

-$0.28

P/E Ratio

-4.64

Dividend

$0.00

Beta (Volatility)

1.40 (Average)

Price

$1.32

Volume

779,001.927

Open

$1.29

Previous Close

$1.31

Daily Range

$1.21 - $1.33

52-Week Range

$0.88 - $1.71

Estimated Earnings Date

Aug 13, 2026

CRDL News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cardiol Therapeutics

Cardiol Therapeutics Inc. is a clinical-stage life sciences company focused on developing anti-fibrotic and anti-inflammatory therapies for cardiovascular disease. The company's lead candidate, CardiolRx, is currently in a pivotal Phase II/III trial aimed at treating complications in hospitalized COVID-19 patients and addressing acute myocarditis.

Products and Services
  • CardiolRx: A cardioprotective treatment for COVID-19 complications
  • Subcutaneous CardiolRx: Targeting cardiac fibrosis and inflammation in heart failure
  • Research and development of innovative therapies for cardiovascular diseases
Growth Outlook
  • CardiolRx is in a multi-national Phase II/III study, enhancing its market potential
  • Expansion into subcutaneous formulations may broaden treatment options
  • Increasing focus on cardiovascular disease aligns with global health trends
Financial Highlights
  • Recent quarterly net income of -10.8 million CAD reflects ongoing R&D investments
  • Cash and short-term investments totaled 27.7 million CAD as of March 31, 2026
  • Current ratio of 4.39 indicates strong liquidity position
Cardiol Therapeutics Inc. operates in the specialized drug manufacturing sector, with a focus on addressing significant unmet needs in cardiovascular health. The ongoing clinical trials and innovative product pipeline position the company for potential growth in a critical area of healthcare. The financial data indicates a commitment to research and development, which is essential for long-term success in the pharmaceutical industry. With a solid cash position and a strategic focus on high-demand therapies, Cardiol Therapeutics Inc. presents an intriguing opportunity for investors interested in the life sciences sector.
AI Generated • Jul 21, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

23

CEO

David G. Elsley, MBA

Website

www.cardiolrx.com

Headquarters

Oakville, ON L6H 0G5, CA

CRDL Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-229.16%

Return on Capital

-190.61%

Return on Assets

-115.74%

Earnings Yield

-21.55%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$151.01MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

115.27M

Volume

779.00K

Avg. Volume

572.28K

Financials (TTM)

Gross Profit

-CA$52.73K

Operating Income

-CA$35.62M

EBITDA

-CA$36.27M

Operating Cash Flow

-CA$24.24M

Capital Expenditure

-CA$60.26K

Free Cash Flow

-CA$24.30M

Cash & ST Invst.

CA$27.74M

Total Debt

CA$116.71K

Cardiol Therapeutics Performance Analysis

Cardiol Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CAD 0N/A
20232023-12-31CAD 0N/A
20242024-12-31CAD 0N/A
20252025-12-31CAD 0N/A
Cardiol Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Cardiol Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CAD -0.38-34.9%
20232023-12-31CAD -0.32-14.9%
20242024-12-31CAD -0.3715.7%
20252025-12-31CAD -0.28-25.6%
Cardiol Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30-20.0%
Q42025-12-3140.1%
Q12026-03-31-38.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

CA$0.00

N/A

Gross Profit

-CA$26.78K

N/A

Gross Margin

0.00%

N/A

Market Cap

$151.01MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$8.39M

N/A

Employees

18

N/A

Net Income

-CA$10.85M

-30.9%

EBITDA

-CA$10.82M

-30.9%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

CA$27.74M

+19.1%

Total Debt

CA$116.71K

-22.5%

Accounts Receivable

CA$340.58K

-1.8%

Inventory

CA$0.00

N/A

Long Term Debt

CA$76.81K

-34.0%

Short Term Debt

CA$39.79K

+16.2%

Return on Assets

-1.16%

N/A

Return on Invested Capital

-1.47%

N/A

Free Cash Flow

-CA$7.58M

-5.8%

Operating Cash Flow

-CA$7.54M

-5.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ASRTAssertio Holdings, Inc.
$23.50+0.00%
IFRXInflaRx N.V.
$1.75+2.94%
CNTBConnect Biopharma Holdings Limited
$1.97-2.48%
VANIVivani Medical, Inc.
$1.33+3.91%

Trending Stocks

Symbol / CompanyPricePrice Chg
SQQQProShares Trust - ProShares UltraPro Short Qqq
$41.43-0.05%
NVDANvidia
$206.64+0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.81+0.07%
INTCIntel
$91.00+0.01%

Questions About CRDL

What is the current price of Cardiol Therapeutics?

Cardiol Therapeutics is trading at $1.31 per share.

What is the 52-week range for Cardiol Therapeutics?

Over the past 52 weeks, Cardiol Therapeutics has traded between $0.88 and $1.71.

How much debt does Cardiol Therapeutics have?

As of the most recent reporting period, Cardiol Therapeutics reported total debt of CA$83.41K.

How much cash does Cardiol Therapeutics have on hand?

Cardiol Therapeutics reported CA$19.83M in cash and cash equivalents in its most recent financial results.

What is Cardiol Therapeutics’s dividend yield?

Cardiol Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services